BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:Europe/Amsterdam X-WR-TIMEZONE:Europe/Amsterdam BEGIN:VEVENT UID:6@vhl-europa.org DTSTART;TZID=Europe/Amsterdam;VALUE=DATE:20241019 DTEND;TZID=Europe/Amsterdam;VALUE=DATE:20241021 DTSTAMP:20241105T143931Z URL:https://vhl-europa.org/events/16th-international-vhl-medical-symposium / SUMMARY:16th International VHL Medical Symposium DESCRIPTION:Join the leading VHL researchers\, physicians\, and experts in Milan!\nWhat: The 16th International VHL Medical Symposium\, hosted by the VHL Alliance and the San Raffaele Scientific Institute\, will bring scien tists\, clinicians and advocates together for two days of collaboration\, idea exchange\, and thought leadership.\n\nWhere: UniSR Campus Milano Olge ttina (Via Olgettina 58\, Milan) on the second floor of the Dibit 1 buildi ng\, in the Caravella S. Maria Lecture Hall.\n\nThis link will provide you with direct step-by-step instructions on how to get there from wherever y ou are coming from: https://maps.unisr.it/spaces/606b1200dad60d30a2348971\ n\nWhen: October 19-20\, 2024\n\nRegistration Fee: Standard $175 / Residen ts $100 / Students FREE [please note that the student registration does no t include catering] / Corporate $750. Click here to register.\n\nLodging: Hotel Raffaele Via Olgettina\, 60\, 20132 Milano MI\, Italy\n\nCME Accredi tation:\n\n\n\n“The 16th International VHL Medical Symposium\, Milan\, I taly 19/10/2024 – 20/10/2024 \, has been accredited by the European Accr editation Council for Continuing Medical Education (EACCME®) with 14.0 Eu ropean CME credits (ECMEC®s). Each medical specialist should claim only t hose hours of credit that he/she actually spent in the educational activit y.”\n\n“Through an agreement between the Union Européenne des Médeci ns Spécialistes and the American Medical Association\, physicians may con vert EACCME® credits to an equivalent number of AMA PRA Category 1 Credit sTM. Information on the process to convert EACCME® credit to AMA credit c an be found at https://edhub.ama-assn.org/pages/applications .\n\n“Live educational activities\, occurring outside of Canada\, recognised by the U EMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activ ities (Section 1) as defined by the Maintenance of Certification Program o f the Royal College of Physicians and Surgeons of Canada.”\nScientific c oordinator:\nDr. Alessandro Larcher\, Milan (Italy)\nScientific committee: \nDr. Ruhee Dere\, Huston – TX (USA)\nDr. Othon Iliopoulos\, Boston – MA (USA)\nProf. Andrea Salonia\, Milan (Italy)\nOrganizing committee:\nJos hua Mann\, Boston – MA (USA)\nJanet Thompson\, Boston – MA (USA)\nAbst ract Submission Details\nThe deadline for abstract submissions is July 3rd . A link to submit abstracts will be provided to event attendees by email following the registration process. Please note that there is a 400 word m aximum for abstract submissions.\n\n\n\n\n\n\n\n\n\nSaturday\, 19th Octobe r 2024\n*Please note that each 20 minute time block will be divided into 1 5 minutes of presentation time and 5 minutes for Q&\;A\n\n\n\n8:30 – 09:00\nRegistration\n\n\n09:00 – 09:05\nWelcome and Introduction\nModera tors: \n\nR. Dere (US)\n\n\nO. Iliopoulos (US)\, \n\nA. Larcher (IT)\,  \n\nA. Salonia (IT)\, \n\nJ. Thompson (US)\n\n\n09:05 – 09:10\nOpening Remarks\nModerator: \n\nK. Rathmell (US)\n\n\nSession 1 – Special Lectu re\n\n\n09:10-09:30\nBelzutifan Development: Intrinsic and Acquired Resist ance\nJ. Brugarolas (US)\n\n\nSession 2 – Clinical management of VHL tum ors – surveillance\, diagnosis\, and treatment\nModerators: \n\nR. van Leeuwaarde (NL)\,\n\nA. Veltri (IT)\n\n\n09:30 – 09:50\nRecommendations for management of VHL-related pancreatic manifestations\nA. Tirosh (IL)\n\ n\n09:50 – 10:10\nIdentification\, surveillance and treatment for VHL-re lated pheochromocytomas and paragangliomas\nK. Pacak (US)\n\n\n10:10 – 1 0:30\nProffered Abstract\nDistinct genomic and immune profiles of kidney c ysts and clear cell renal cell carcinomas in von Hippel-Lindau syndrome\nF . Corea (IT)\n\n\n10:30 – 10:50\nCoffee Break\n\n\n10:50 – 11:10\nRadi ation therapy in ccRCC: potential application in VHL disease\nR. van Leeuw aarde (NL)\n\n\n11:10 – 11:30\nSystematic assessment of surgical outcome s in hereditary ccRCC\nA. Larcher (IT)\n\n\n11:30 – 11:50\nProffered Abs tract\nDeveloping Prophylactic and Therapeutic Gene Therapy for von Hippel -Lindau Syndrome Using Adeno-Associated Vectors\nP. Moeini (ES)\n\n\nSessi on 3 – Exploring the Molecular Basis of VHL disease – Genetics of VHL\ nModerator: P. Carrera (IT)\n\n\n11:50 – 12:10\nModeling the von Hippel Lindau disease by using hIPSC\nB. Gardie (FR)\n\n\n12:10 – 12:30\nHypoxi c stress favors somatic mutation in pre-cancer renal cells\nI. Franco (IT) \n\n\n12:30 – 12:50\nGenetic analysis of VHL-related ccRCC\nS. Gad  Lap iteau (FR)\n\n\n12:50 – 13:10\nProffered Abstract\nOncostatin M reshapes the tumor microenvironment during ccRCC development by inducing epigeneti c changes in endothelial cells\nH.H. Nguyen Tran (TW)\n\n\n13:10 – 14:20 \nLunch / Poster Session 1\n\n\n\n \n\nPosters will not be discussed\, bu t they will be displayed and accessible during the lunch session and will cover the following topics: VHL genetics\, Molecular basis of VHL disease\ , Clinical management of VHL-related tumours – surveillance\, diagnosis and treatment\,  Systemic agents that can be exploited in VHL\, Patients ’ associations\n\n \;\n\nPOSTERS LIST AND AUTHORS:\n\n1. Genetic del etion of the primary cilium promotes malignant cyst formation and induces masculine ccRCC phenotypes in\n\nfemale mice – M. Adlesic (DE)\n\n2. Som atostatin receptor 2A expression in von Hippel‐Lindau related hemangiobl astomas – S. Ahmad (NL)\n\n3. Structural Characterization of Hypoxia Ind ucible Factor α – Prolyl Hydroxylases Interaction through MD Simulation – G.\n\nCamagni (IT)\n\n4. Rassf1a mutation causes accumulation of chro mosomal instability and induces gene expression changes characteristic of\ n\nccRCC – A. Catalano (DE)\n\n5. The von Hippel-Lindau protein regulate s androgen receptor in renal cancer – A. Falconieri (IT)\n\n6. Rsume Exp ression as A Prognostic Indicator in Clear Cell Renal Cell: Carcinoma Invo lvement of Cilia and Ros Pathways – D.\n\nGonilski (AR)\n\n7. In silico unveiling the Androgen Receptor’s hidden role in Clear cell renal cell c arcinoma (ccRCC) through Interaction with\n\nthe von Hippel-Lindau Protein – F. Gregoris (IT)\n\n8. Exploration of the MyVHL Natural Patient Histo ry Study: Patient Demographics\, Cancer and Tumor Prevalence\, and\n\nImpa ct of Smoking on Health Outcomes in Von Hippel Lindau Disease – R. Klein (US)\n\n9. VHL inactivation and tyrosine kinase inhibitors prevent PD-L1 degradation – X. Liu (US)\n\n10. Distinctive communication between lipid -laden TAMs and VHL-deficient renal tubule cells contributes to lipid\n\na ccumulation in tumor cells and ccRCC development – N. Nguyen Thi (TW)\n\ n11. Patient-Specific Simulation of Retinal Hemangioblastoma Informed with Optical Coherence Tomography – F. Pradelli (IT)\n\n12. Synthetic lethal ity of VHL deficiency with CDK inhibition – O. Razorenova (CA)\n\n13. SE TD2 regulates cytoskeleton function in ccRCC – R. Roffo (DE)\n\n14. Hema ngioblastomatosis Associated With Von Hippel Lindau Syndrome: Case Series – L. Sussmann (CO)\n\n15. Epidemiology of von Hippel-Lindau Disease in J apan: A Nationwide Population-based Cohort Study – A. Takahashi (JP)\n\n 16. Contribution of NGS multi-gene panel testing to the genetic diagnosis of renal cell carcinoma patients – R. Vibert (FR)\n\n17. Investigating t he role of PBRM1 in a murine cancer model for ccRCC – C. Witt (DE)\n\n18 . Investigating the Role of Oncometabolites in von Hippel Lindau disease-r elated Pancreatic Neuroendocrine Cancer – Y.\n\nYossef (IL)\n\n19. 810 n m infrared transpupillary thermotherapy for treatment the juxtapapillary r etinal capillary hemangioblastoma. Case\n\nreport – T. Zakaraiia (RU)\n\ n20. VHL Cerebellar Hemangioblastoma Origin: Postnatal Developmentally Arr ested Basket/Stellate Cells of\n\nPurkinje/Molecular Layers in Humans – S. Shively (US)\n\n \;\n\n21. Functional study of VHL in the initiatio n of renal carcinogenesis – V. Poillerat (FR)\n\n22. Hypoxic stress fav ours somatic mutation in normal kidneys – J.P. Margaria (IT)\n\n\nSessio n 4 – Exploring the Molecular Basis of VHL disease – Tumor heterogenei ty in VHL ccRCC\nModerators: R. Bernardi (IT)  Ian Frew (DE)\n\n\n14:20 – 14:40\nInfluence of the tumour microenvironment and somatic mutations on tumour growth\nT.J. Mitchell (UK)\n\n\n14:40 – 15:00\nDistinct transc riptomic and genomic profiles of kidney cysts and clear cell renal cell ca rcinomas in Von Hippel-Lindau disease\nI. Rowe (IT)\n\n\n15:00 – 15:20\n VHL disease: repeated clonal evolution in a lifetime\nS. Turajilic (UK)\n\ n\n15:20 – 15:40\nProffered Abstract\nKdm5c mutation cooperates with Vhl and Pbrm1 mutations to induce ccRCC in mice\nF. Cuomo (DE)\n\n\n15:40 – 16:00\nCoffee Break\n\n\nSession 5 – Clinical management of VHL tumors – Live Tumor Board\nModerators: \n\nF. De Cobelli (IT)\, \n\nO. Iliopo ulos (US)\, \n\nE. Jonasch (US)\, \n\nS. Mukai (US)\, \n\nA. Tirosh (IL )\n\n\n16:00 – 16:30\nCase Presentation of VHL Disease 1\nThe first clin ical case is about a 29 year-old woman who was enrolled in the HSR VHL Pro gram in 2022. At admission\, she presented with significant urologic manif estations of the disease\, characterised by multiple solid lesions in both kidneys. After multidisciplinary team discussion\, the patient was select ed for open bilateral tumorectomy with intraoperative thermoablation of th e renal tumours. \nL. Salerno (IT)\n\n\n16:30 – 17:00\nCase Presentatio n of VHL Disease 2\nThe second clinical case is about a 52 year-old man pr esenting with a metastatic kidney cancer associated with VHL disease. He h as undergone multiple surgeries\, including bilateral radical nephrectomy\ , and he is now under regular dialysis. Initially\, he began systemic ther apy\, which was discontinued due to significant side effects. Recently\, h e received radiotherapy for retroperitoneal lymphadenopathy\, a manifestat ion of the disease. \nS. Ahmad  (NL)\n\n\n17:00 – 17:10\nClosing Remar ks\nR. Dere (US)\nO. Iliopoulos (US)\, A. Larcher (IT)\, A. Salonia (IT) \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSunday\, 20th October 2024\n*Please note that each 20 minute time block will be divided into 15 minutes of present ation time and 5 minutes for Q&\;A\n\n\n08:25 – 08:30\nWelcome and In troduction\nR. Dere (US)\nO. Iliopoulos (US)\, A. Larcher (IT)\, A. Salo nia (IT)\n\n\nSession 1 – Special Lecture\n\n\n08:30 – 09:10\nVHL 1984 -2024: Evolution of Diagnosis\, Management\, Surgery and Therapy\nM. Lineh an (US)\n\n\nSession 2 – Clinical management of VHL tumors – Systemic Agents for VHL\nModerators: \n\nO. Iliopoulos (US)\, \n\nA. Necchi (IT)\ n\n\n09:10 -09:30\nMid-term outcomes following HIF inhibition in VHL disea se\nE. Jonasch (US)\n\n\n09:30 – 09:50\nQuality of life and toxicity und er HIF inhibitors in hereditary and sporadic ccRCC\nR. Srinivasan (US)\n\n \n09:50 – 10:10\nImpact of HIF-2a Inhibition on CNS tumors\nO. Iliopoulo s (US)\n\n\n10:10 – 10:30\nCoffee Break\n\n\nSession 3 – Signal Transd uction and Modeling in VHL Disease\nModerators: \n\nA. Boletta (IT)\, \n \nR. Srinivasan (US)\n\n\n10:30 – 10:50\nStudy New VHL Signaling Axis in Kidney Cancer\nQ. Zhang (US)\n\n\n10:50 – 11:10\nLinking VHL and SETD2 in a Common Oncogenic Pathway Converging at the Mitotic Spindle.\nR. Dere (US)\n\n\n11:10 – 11:30\nTranscriptional Control of Renal Carcinogenesis \nS. Vanharanta (FI)\n\n\n11:30 – 11:50\nCross Species Functionalization Of The Cancer Genome\nG. Genovese (US)\n\n\n11:50 – 12:10\nSex-specific differences in ccRCC: separating the functions of KDM5C and KDM5D\nI. Fre w (DE)\n\n\n12:10 – 12:30\nProffered Abstract\nSynthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma\nX. Lu (US)\n\n\n12:3 0 – 13:50\nLunch / Poster Session 2\n\n\n \n\nPosters will not be discu ssed\, but they will be displayed and accessible during the lunch session and will cover the following topics: VHL genetics\, Molecular basis of VHL disease\, Clinical management of VHL-related tumours – surveillance\, d iagnosis and treatment\,  Systemic agents that can be exploited in VHL\, Patients’ associations\n\n \;\n\nPOSTERS LIST AND AUTHORS:\n\n1. Ge netic deletion of the primary cilium promotes malignant cyst formation and induces masculine ccRCC phenotypes in\n\nfemale mice – M. Adlesic (DE)\ n\n2. Somatostatin receptor 2A expression in von Hippel‐Lindau related hemangioblastomas – S. Ahmad (NL)\n\n3. Structural Characterization of Hypoxia Inducible Factor α – Prolyl Hydroxylases Interaction through MD Simulation – G.\n\nCamagni (IT)\n\n4. Rassf1a mutation causes accumula tion of chromosomal instability and induces gene expression changes charac teristic of\n\nccRCC – A. Catalano (DE)\n\n5. The von Hippel-Lindau pro tein regulates androgen receptor in renal cancer – A. Falconieri (IT)\n\ n6. Rsume Expression as A Prognostic Indicator in Clear Cell Renal Cell: Carcinoma Involvement of Cilia and Ros Pathways – D.\n\nGonilski (AR)\n\ n7. In silico unveiling the Androgen Receptor’s hidden role in Clear ce ll renal cell carcinoma (ccRCC) through Interaction with\n\nthe von Hippel -Lindau Protein – F. Gregoris (IT)\n\n8. Exploration of the MyVHL Natur al Patient History Study: Patient Demographics\, Cancer and Tumor Prevalen ce\, and\n\nImpact of Smoking on Health Outcomes in Von Hippel Lindau Dise ase – R. Klein (US)\n\n9. VHL inactivation and tyrosine kinase inhibito rs prevent PD-L1 degradation – X. Liu (US)\n\n10. Distinctive communica tion between lipid-laden TAMs and VHL-deficient renal tubule cells contrib utes to lipid\n\naccumulation in tumor cells and ccRCC development – N. Nguyen Thi (TW)\n\n11. Patient-Specific Simulation of Retinal Hemangiobla stoma Informed with Optical Coherence Tomography – F. Pradelli (IT)\n\n1 2. Synthetic lethality of VHL deficiency with CDK inhibition – O. Razor enova (CA)\n\n13. SETD2 regulates cytoskeleton function in ccRCC – R. R offo (DE)\n\n14. Hemangioblastomatosis Associated With Von Hippel Lindau Syndrome: Case Series – L. Sussmann (CO)\n\n15. Epidemiology of von Hip pel-Lindau Disease in Japan: A Nationwide Population-based Cohort Study – A. Takahashi (JP)\n\n16. Contribution of NGS multi-gene panel testing to the genetic diagnosis of renal cell carcinoma patients – R. Vibert (F R)\n\n17. Investigating the role of PBRM1 in a murine cancer model for ccR CC – C. Witt (DE)\n\n18. Investigating the Role of Oncometabolites in vo n Hippel Lindau disease-related Pancreatic Neuroendocrine Cancer – Y.\n\ nYossef (IL)\n\n19. 810 nm infrared transpupillary thermotherapy for treat ment the juxtapapillary retinal capillary hemangioblastoma. Case\n\nreport – T. Zakaraiia (RU)\n\n20. VHL Cerebellar Hemangioblastoma Origin: Post natal Developmentally Arrested Basket/Stellate Cells of\n\nPurkinje/Molecu lar Layers in Humans – S. Shively (US)\n\n21. Functional study of VHL in the initiation of renal carcinogenesis – V. Poillerat (FR)\n\n22. Hypo xic stress favours somatic mutation in normal kidneys – J.P. Margaria (I T)\n\n\nSession 4 – Clinical management of VHL tumors – Extrarenal Pri maries\nModerators: \n\nA. M. Ferrara (IT)\, \n\nS.Partelli (IT)\, \n\n A. Tirosh (IL)\n\n\n13:50 – 14:10\nMinimally invasive treatment of retin al hemangioblastoma\nS. Mukai (US)\n\n\n14:10 – 14:30\nCNS Hemangioblast omas – the role of surgery in the modern era\nP. Chittiboina (US)\n\n\n1 4:30 – 14:50\nCNS hemangioblastoma – the reasons for surgery upfront\n A Feletti (IT)\n\n\n14:50 – 15:10\nOptimizing surgical outcomes for here ditary pancreatic NET\nN. Nilubol (US)\n\n\n15:10 – 15:30\nProffered Abs tract\nGermline VHL-gene alterations are associated with increased risk of cardiovascular disease – al large population study\nR. Halperin (IL)\n\ n\n15:30 – 15:50\nCoffee Break\n\n\nSession 5 – Patient associations a nd policymaking\nModerators:\n\nR. Giles (NL)\, \n\nF. Lombardi (IT)\, \ n\nJ. Mann (US)\n\n\n15:50 – 16:10\nAddressing the Psychosocial Needs of Individuals living with VHL\nG. Perez (US)\n\n\n16:10 – 16:30\nCurrent unmet need of European VHL Families\nR. Giles (NL)\n\n\n16:30 – 16:45\nS tate of VHLA\nJ. Thompson (US)\n\n\n16:45 – 17:00\nClosing Remarks\nR. D ere (US)\nO. Iliopoulos (US)\, A. Larcher (IT)\, A. Salonia (IT)\n\n\n\n \n\n\n\nMeet some of the 2024 speakers\n\nMarston Linehan\, MD\nDr. Lineha n pioneered the study of the genetic basis of kidney cancer. His team iden tified the genes for the common forms of kidney cancer and described the p athways of these kidney cancer genes. His recent studies targeting the met abolic basis of kidney cancer have resulted in the regression of metastati c cancer in patients with type 1 and type 2 papillary kidney cancer. As Ch ief\, Dr. Linehan oversees the Branch’s clinical/translational research program\, which emphasizes new approaches to the therapies of genitourinar y cancers\, diagnostic and prognostic evaluation of solid GU tumors\, and the development of innovative surgical and adjunctive approaches to the tr eatment of patients with primary and metastatic urologic cancer.\n\n\nEric Jonasch\, MD\nEric Jonasch\, MD is Professor in the Department of Genitou rinary Medical Oncology\, Division of Cancer Center at the University of T exas M. D. Anderson Cancer Center in Houston\, Texas.\n\nDr. Jonasch is di rector of the VHL Clinical Center at the MD Anderson Cancer Center and is involved in tissue-based translational research in renal cell carcinoma an d VHL disease. He leads the Department of Defense Kidney Cancer and VHL Di sease Consortia. Dr. Jonasch is in charge on an ongoing laboratory researc h effort evaluating the determinants of response and resistance to therapy in renal cell carcinoma and VHL disease. Dr. Jonasch’s current work foc uses on understanding the drivers of renal cell carcinoma tumor ontogeny\, and the development of informative models of tumor-microenvironmental int eraction. Dr. Jonasch serves as Vice-Chair of the NCCN Kidney Cancer Guide line Panel and is a Board member of the International Kidney Cancer Coalit ion.\n\n\nOthon Iliopoulos\, MD\, PhD\nOthon Iliopoulos is an oncologist a t Massachusetts General Hospital\, where he serves as the Clinical Directo r of the VHL Disease/Familial Renal Cell Cancer Program. He is also an Ass ociate Professor of Medicine at Harvard Medical School and at the Center f or Cancer Research at MGH. Dr. Iliopoulos is a VHL Alliance Research Grant Recipient and is a Clinical Investigator for the MK-6482 (formerly PT-297 7) clinical trial. His lab is involved in research pertaining to the main mechanisms underlying the reprogramming of cancer cell metabolism and canc er angiogenesis with the goal to develop mechanism-based strategies for se lectively killing cancer cells. Dr. Iliopoulos is the Chair of the Clinica l Advisory Council and the Research Council.\n\n\nJames Brugarolas\, M.D.\ , Ph.D.\nJames Brugarolas\, M.D.\, Ph.D.\, is a practicing oncologist and a tenured Professor of Internal Medicine at UT Southwestern Medical Center (UTSW). He is the Sherry Wigley Crow Endowed Chair in Cancer Research and the Founding Director of the Kidney Cancer Program\, one of two recognize d by the NCI with a SPORE award. Spanning the spectrum from fundamental to clinical research\, discoveries from his laboratory identified kidney can cer driver genes\, set the foundation for the first genetic classification of the most common type (ccRCC)\, led to the first mouse models reproduci ng ccRCC\, and identified the first core dependency. His team is credited with advancing a first-in-class HIF-2 inhibitor developed at UTSW by valid ating HIF-2 as a target in kidney cancer and through the identification of putative biomarkers and mechanisms of resistance. A member of ASCI and th e NCI Renal Cancer Task Force\, Dr. Brugarolas serves as chair of the scie ntific advisory board of the Academy of Kidney Cancer Investigators. Follo wing a residency in internal medicine at Duke University Medical Center\, he completed a fellowship in oncology at the Dana-Farber Cancer Institute\ , where he trained with Nobel Laureate William G. Kaelin\, Jr\, M.D. He ho lds an M.D. from the University of Navarra and a Ph.D. from MIT\, where he trained with Tyler Jacks\, Ph.D.\n\n\nRamaprasad Srinivasan\, M.D.\, Ph.D .\nDr. Srinivasan is developing precision\, targeted treatment strategies and clinical trials for patients with both hereditary and non-hereditary f orms of kidney cancer. Currently\, he is investigating a variety of mechan ism-based treatment strategies in clear cell and papillary kidney cancer\, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau\, hereditary leiomyomatosis and renal cell cancer (HLRCC) and hereditary pa pillary renal cell cancer (HPRC).\n\n\nKarel Pacak\, MD\, PhD\, DSc\nDr. K arel Pacak graduated summa cum laude from Charles University\, Prague\, Cz ech Republic in 1984. In 1990 he began his postdoctoral fellowship at NIND S Under Drs. Kopin and Goldstein. Then in 1995 Dr. Pacak began his residen cy in internal medicine at the Washington Hospital Center under Dr. L. War tofsky\, followed by a fellowship in endocrinology\, diabetes\, and metabo lism at NIH. He was Board certified in 1998 and 1999 in those disciplines. In 1998 he established a new Program for Neuroendocrine Tumors focusing o n pheochromocytoma and paraganglioma at NICHD. He received his Ph.D. in199 3 and his D.Sc. in 1998 in the field of neuroendocrinology from Charles Un iversity. In 2006 he was awarded a lifetime professorship in Internal Medi cine at Charles University. Dr. Pacak is an internationally recognized exp ert in the diagnosis and treatment of neuroendocrine tumors\, especially p heochromocytoma and paraganglioma. Dr. Pacak also established the Internat ional Symposia on Pheochromocytoma. He also helped co-found a new Asian Al liance for the Study of Neuroendocrine Tumors in 2010. He is a recipient o f numerous awards including the Peter Heimann Memorial Award at Yale Unive rsity\, International Association of Endocrine Surgeons\; NIH Director’s Mentoring Award\, Award for Cure from Pheo &\; Para Alliance\, NICHD D irector’s Award of Merit\, Pincus Taft Memorial Lecture the Highest Awar d from Endocrine Society of Australia\, Jessenius Gold Medal from Slovak A cademy of Sciences\, Outstanding Clinical Endocrinologist from the America n Association of Clinical Endocrinologists and recently Outstanding Clinic al Investigator (to be given in 2022) from the US Endocrine Society as wel l as Team Science Award from American Association for Cancer Research. Dr. Pacak is the author of more than 720 scientific peer-reviewed articles\, 150 book chapters\, and 6 books.\nMilano\nMilan is a vibrant and exciting city that offers a wealth of experiences for everyone. It is home to some of the most renowned museums and galleries in the world\, including the La st Supper Fresco\, the Pinacoteca di Brera and the Leonardo da Vinci Museu m\, but also of iconic landmarks such as the Gothic-style Duomo di Milano and the imposing Sforza Castle. Milan is not only the capital of Italian f ashion but also a foodie’s paradise\, offering a diverse range of culina ry experiences that showcase the best of Italian cuisine. Visitors can enj oy everything from traditional street food to Michelin-starred fine dining . No matter the day or the time\, Milano is alive: music festivals\, art e xhibitions\, theatrical performances and much\nmore are there to entertain any kind of guest.\n\n \nCongress venue\nCongress Centre HSR\nVia Olgett ina 58/60 – Milano\nBuilding Dibit 1\n\nThe San Raffaele Research Hospit al is a highly specialized multi-disciplinary medical center of world impo rtance\, which embodies the integrity of the treatment\, clinical research and teaching activities. San\nRaffaele provides treatment in all existing medical fields\, which allows this center to take care of the most\ncompl ex patient cases. The Hospital is recognized as IRCCS (Scientific Institut e for Research and Healthcare) for its research in molecular medicine and innovative treatments application\, such as the gene therapy.\n\nThe hospi tal is a multi-specialty center with more than 50 clinical specialties ava ilable and with over 1600 beds\; it is accredited by the Italian National Health System to provide care to both public and private\, Italian and int ernational patients.\n\nIn 2018 the San Raffaele Hospital performed over 5 1\,000 patient admissions\, 72\,000 emergency room encounters and delivere d over 1.5 million outpatient medical services. It is widely regarded as t he most celebrated hospital in the country and among the most reputable me dical centers in Europe. San Raffaele’s wards and operating theatres are equipped with the most advanced machines\, such as PET\, PET/CT\, Gamma K nife\, Cyber Knife\, Rapid Arc\, Tomotherapy. San Raffaele’s Radiotherap y Unit was the first place in Europe to install Tomotherapy in 2004. Nowad ays this Unit confirms to be one of the most experienced worldwide\; it ha s developed numerous protocols for cancer treatment of the prostate\, brea st\,\ncentral nervous system\, brain\, liver\, pancreas\, gastrointestinal tract\, lungs\, and others. The Oncological\nBoard of the Hospital consis ting of diagnosticians\, clinical oncologists\, immunologists\, surgeons a nd\nradiotherapists\, hold weekly meetings to discuss oncological patients ’ pathways in a multidisciplinary manner.\n\nBeside its Cancer Center\, San Raffaele is well-known for its medical know-how in cardiology and card iac surgery\, neurology and neurosurgery\, gastroenterology and gastrointe stinal tract surgery\, liver surgery\, pancreas surgery\, transplant medic ine\, gynecology and obstetrics\, urology\, dermatology\, ophthalmology\, immunology\, rheumatology and pediatrics.\n\nSan Raffaele is a pioneer in the field of gene medicine and treatment of rare immunologic and genetic d iseases. San Raffaele Scientific Institute is where the first in the world gene therapy with stem cells was created\, named Strimvelis\, for patient s affected by ADA-SCID syndrome.\n\nThe Research at the San Raffaele Hospi tal focuses on integrating basic\, translational and clinical research to provide the most advanced care to the patients. It counts on over 1\,500 s cientists\, working in state-of-the-art facilities covering a surface of 1 30\,000 square meters\, and have produced over 1\,446 scientific publicati ons in 2018.\n\nResearch at San Raffaele aims at understanding the mechani sms underlying a variety of important human diseases and at identifying ne w targets and new therapeutic strategies to treat them.\n\nThe San Raffael e Hospital hosts the Università Vita-Salute San Raffaele\, a fully privat e university with a\ncomplete Medical School (including specialty courses and residencies)\, Nursing School\, a Psychology graduate and post-graduat e programs\, and Allied Health Professions School. The mission of the Vita -Salute\n\nSan Raffaele University is to answer the question “Quid est h omo?” in the belief that the human being is a biological\, psychological and spiritual unicum. Since 2010 the San Raffaele Hospital also hosts the \nInternational MD Program\, the only graduate program accredited to licen se Medical Doctors in both Europe and North America.\nAccessibility\nMetro 2 (Green LINE) from city centre to Cascina Gobba stop\nFrom Cascina Gobba there is a private train line that will bring to HSR in 5 minutes\nVisa r equirements\nDepending on your citizenship\, you may need to obtain a VISA before coming to Italy. For detailed\ninformation\, visit the website of the Italian Ministry of Foreign Affairs: http://vistoperitalia.esteri.it/ home/en\nIt is the delegate’s responsibility to investigate the VISA req uirements for Italy and to apply for a VISA\, if\nnecessary.\n\nThe confer ence organizers and/or the Organizing Secretariat will not directly contac t embassies and\nconsulates on behalf of VISA applicants.\n\nVisas should be requested at least 2 months before departure\, you can apply also later but it is not sure it will be released on time\, as the application proce ss can take several weeks.\n\nSpecial information and questions for VISA c an be requested to the Congress Secretariat at the e-mail\naddress: visa@ aimgroup.eu.\nInvitation letter\nThe invitation letter to the conference c an be requested to the Congress Secretariat after the registration is paid and accepted.\n\nPlease contact us at: VHL2024@aimgroup.eu Please note that the standard invitation letter of the conference may NOT be suitable for VISA application of those countries with special dedicated procedures. \n\nPlease check your status and action requested to you as explained in t he Visa Information Area.\nSuggested accommodation\nHotel Rafael ***\nVia Olgettina\, 60 – 20132 Milano\nEmail: info@rafaelhotel.it\nhttps://www. rafaelhotel.it/\nLocated near the Conference venue\n\nHotel NH Milano 2 ** **\nStrada di Olgia Nuova – 20090 Segrate Milano\nEmail: nhmilano2@nh-h otels.com\nWebsite\n\n15/20 min walking distance from the venue\n\n \nHow to reach Milan\nRailway station\nStazione Centrale\nIt is the second larg est and second busiest station in Italy\, located 3 km away from the Duomo and is connected by 2 metro lines (M3 yellow and M2 green). The imposing and majestic railway station is a crucial hub for the city’s services an d shopping district and the main departure point for the High-Speed train and rail connections\nwith the rest of Europe.\nMalpensa airport\nThe most important intercontinental hub in Southern Europe\, located just at about 50 km from Milan\ncity center and quickly reachable by car\, train (high- speed Malpensa Express train)\, bus or taxi.\nMalpensa airport is in a str ategic position in the financial and productive heart of Europe. It is loc ated just over 50 kilometres from Milan and is quickly reachable by car\, train\, bus or taxi. It is one of the most important airports in Europe\, offering more than 2\,500 direct flights each week and numerous interconti nental and long-\nhaul destinations. It is also the leading Italian airpor t in terms of freight transport.\n\nFROM/TO MALPENSA AIRPORT\nMalpensa Exp ress Train: the airport can be easily reached from the center of Milan wit h the Malpensa Express train from Milan Cadorna\, Milan Centrale\, and Mil an Porta Garibaldi stations. Malpensa Express train stops at Malpensa Term inals 1 and 2. Trains scheduled every 30 minutes. Travel Time: Cadorna (43 minutes) – Central\nStation (53 min) – Porta Garibaldi (41 minutes)\n \nBy Coach: bus connections between Milan Central Station and the two ter minals of Malpensa Airport are\noperated by three bus lines: Terravision\, Malpensa Bus Express (Autostradale) and Malpensa Shuttle (Air\nPullman). Average travel time: 45 minutes\n\nBy car: Milan Malpensa airport is easi ly reachable by car using the A8 / A9 motorway if you are coming from\nMil an or located to the North and East of the airport\, the A4 motorway if yo u are coming from the West or the\nSouth.\n\nBy taxi: various radiotaxi s ervices are available at both Milan Malpensa Airport Terminals. The taxi r anks are\nlocated at the ARRIVALS\, at the ground floor\, at gate 6 of Ter minal 1 and at gate 4 at Terminal 2. Fixed taxi fare\nfrom/to Malpensa to/ from Milan: 110 €\nLinate airport\nThe city airport is located 7 km from downtown and quickly reachable by car\, metro\, bus or taxi.\nMilan Linat e Airport is the second-largest airport serving the city and is an inner-c ity airport\, located just 7 km from central Milan.\n\nFROM/TO LINATE AIRP ORT\nBy Metro: the M4 blue line connects Linate airport to the city center .\n\nBy Train: it is possible to reach Milan Linate airport by train arriv ing at the Milan Forlanini station\, directly connected to the airport thr ough the urban bus line 73 (7 stops for a journey of about 10 minutes).\n\ nBy Coach: the bus connections between the city of Milan and the neighbori ng municipalities and Linate Airport are operated by various bus lines: AT M\, Airbus\, Starfly\, Autoguidovie\, and Air Pullman. Travel time: to/fro m\nMilan City Centre (Duomo): 60 minutes – to/from Milan Central Station : 25 minutes\n\nBy Car: Milan Linate airport can be easily reached by car from the North (A4/A51)\, from the West (Viale\nForlanini) and from the Ea st (A35-Brebemi) via the Rivoltana provincial road.\n\nBy Taxi: several ra diotaxi services are available at Milan Linate. The taxi ranks are located at the ARRIVALS\, at the ground floor.\nMilan Bergamo airport (Orio al se rio)\nLow-cost companies’ airport located at 45 km north-east of Milan a nd easy reachable by car (A4)\, by\nbus or taxi.\n\nMilan Bergamo Airport is the third busiest international airport in Italy. The airport is 45 km north-east of Milan and is mainly operated by low cost companies.\n\nFROM/ TO MILAN BERGAMO AIRPORT\nBy Train: you can arrive by train to Bergamo tra in station and use the convenient bus service ATB which in just\n10 minute s will bring you to Milan Bergamo airport (departures every 15 minutes).\n \nBy Coach: the bus connections to the centre of Milan are operated by dif ferent bus companies: Terravision\,\nAutostradale\, Orio Shuttle\, Flixbus . Travel time to Milan Central Station: 50 minutes.\n\nBy car: for those c oming on the A4 from Milan it is recommended to exit at Bergamo and follow for Milan Bergamo Airport. For those coming on the A4 from Brescia\, the recommended exit is Seriate.\n\nTaxi: at the arrivals exit you will find t he taxi zone (110/130 €).\n\n\n\n LOCATION:UniSR Campus Milano Olgettina\, Via Olgettina 58\, Milan\, Italy X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Via Olgettina 58\, Milan\, Italy;X-APPLE-RADIUS=100;X-TITLE=UniSR Campus Milano Olgettina:geo:0,0 END:VEVENT BEGIN:VTIMEZONE TZID:Europe/Amsterdam X-LIC-LOCATION:Europe/Amsterdam BEGIN:DAYLIGHT DTSTART:20240331T030000 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST END:DAYLIGHT END:VTIMEZONE END:VCALENDAR